2Utimura R, Fujihara CK, Matter AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney lnt,2003,63( 1 ) :209 -216.
3Martin T et al. Eur J Immunol, 1997,27 : 1091 - 1097.
7Ross R. Atheroselerosis is an inflammatory disease. Am Heart J, 1999,138(5 ,part 2) :419.
8De Lemos. IA, Morrow DA, Sabetine MS, et al. As3ociation betweenplasma levels of monocyte chemoattraetant protein-1 and long4erm clinical outcomes in patients with acute coronary syndromes. Circulation ,2006 : 107:690.
5[1]Sartipy P,Loskutoff DJ.Monocyte chemoattractant protein 1 in obesity and insulin resistance[J].Proc Natl Acad Sci USA,2003,100(12):7265-7270.
6[2]Haiyan X,Glenn TB,Qing Y,et al.Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance[J].J Clin Invest,2003,112(12):1821-1830.
7[3]Atsuko M,Koji M,Hitomi I,et al.Inhibition of monocyte chemoattractant protein-1 expression in cytokine-treated human lung epithelial cells by thiazolidinedione[J].Chest,2001,120(4):1293-1300.
8[4]Simeoni E,Hoffmann MM,Winkelmann BR,et al.Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus[J].Diabetologia,2004,47(9):1574-1580.
9[5]Steinmetz OM,Panzer U,Harendza S,et al.No association of the –2518 MCP-1 A/G promoter polymorphism with incidence and clinical course of IgA nephropathy[J].Nephrol Dial Transplant,2004,19(3):596-601.
10[6]Rovin BH,Lu L,Saxena R.A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression[J].Bioc Biop Res Comm,1999,259(2):344-348.
